This edition of Lung Cancer Considered discusses important science presented at the recently completed European Lung Cancer Congress, the multidisciplinary lung cancer meeting co-organized by ESMO and IASLC. Dr. Enriqueta Felip and Dr. Fabrice Barlesi share their interpretation of the following clinical trials presented at ELCC:

Adagrasib (MRTX849) -- phase Ib expansion and phase II monotherapy cohorts

CheckMate 9LA -- randomized 719 patients with EGFR/ALK wild type NSCLC to standard chemotherapy or 2 cycles of chemotherapy with nivolumab and Ipilimumab

KEYNOTE-407-- randomized squamous NSCLC to carboplatin with choice of nab/ paclitaxel or paclitaxel, and either pembrolizumab or placebo

AMG 757-- BiTE: bispecific T-cell engager targeting DLL3 and engaging CD3

CAMEL-sq trial-- phase III randomized trial in patients with advanced squamous NSCLC